Pharmaceutical company payments to medical school deans and university hospital directors in Japan: a nationwide cross-sectional study

Clicks: 2
ID: 332870
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #152 of 155 articles by views in International journal for quality in health care : journal of the International Society for Quality in Health Care

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 155 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Financial relationships between pharmaceutical companies and the leaders of academic medical institutions may generate institutional conflicts of interest, yet payments to medical school deans and university hospital directors have not been examined nationally. We assessed the magnitude, concentration, and specialty pattern of pharmaceutical company payments to the leaders of all Japanese academic medical centres. Methods In this nationwide cross-sectional study, we identified the deans and main-hospital directors of all 82 universities with a medical school in Japan for fiscal year 2023 (82 deans and 84 directors). Using payment disclosures from companies affiliated with the Japan Pharmaceutical Manufacturers Association, we aggregated personal payments (lecture, manuscript, and consulting fees) to each leader and described their amount, concentration, and distribution by specialty and payment category. Results Overall, 67 of 82 deans (81.7%) and 77 of 84 hospital directors (91.7%) received payments. Total payments were US$901,128 for deans (median US$4,894) and US$1,843,565 for directors (median US$14,031). Payments were highly concentrated: the top decile of recipients accounted for 43.9% (deans) and 36.4% (directors) of the total, and lecture fees comprised 85.2% and 88.5% of payments, respectively. The highest-paid specialties were orthopaedic surgery, urology, and pharmacology among deans, and respiratory medicine, urology, and haematology among directors. Conclusion Pharmaceutical payments to the leaders of Japanese academic medical centres were common, substantial, and concentrated among a small number of individuals and specialties, supporting the case for prohibiting personal promotional payments to institutional leaders while they hold office, with public disclosure as a minimum floor rather than an endpoint.
Reference Key
openalex_W7222925546 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Keita Shimizu, Akemi Hara, Piotr Ozierański, Ivan D. Florez, Yangqin Xun, Janne Anton Markus Estill, Yaolong Chen, Yudai Kaneda, Tetsuya E. Tanimoto, Akihiko Ozaki
Journal International journal for quality in health care : journal of the International Society for Quality in Health Care
Year 2026
DOI
10.1093/intqhc/mzag170
URL
https://doi.org/10.1093/intqhc/mzag170
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.